Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Once submitted, we will try and place you in contact with a suitable Split-Beam Spectrophotometers supplier within 48 hours.

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

Get Started! Welcome to your new Black Diamond Log Splitter Parts Diagram user manual. This guide will walk you through everything you need to know to operate and maximize your experience. To ensure a ...